PUBLISHER: TechNavio | PRODUCT CODE: 1693122
PUBLISHER: TechNavio | PRODUCT CODE: 1693122
The active pharmaceutical ingredient (API) market in India is forecasted to grow by USD 11184 million during 2024-2029, accelerating at a CAGR of 7.4% during the forecast period. The report on the active pharmaceutical ingredient (API) market in India provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing number of type ii drug master files (DMF), growing emphasis on biosimilars manufacturing, and growing need to focus on core competencies.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
Market Scope | |
---|---|
Base Year | 2025 |
End Year | 2029 |
Series Year | 2025-2029 |
Growth Momentum | Accelerate |
YOY 2025 | 6.8% |
CAGR | 7.4% |
Incremental Value | $11184 mn |
Technavio's active pharmaceutical ingredient (API) market in India is segmented as below:
By Manufacturing Type
By Type
By Product Type
By Application
By Geographical Landscape
This study identifies the paradigm shift in API manufacturing as one of the prime reasons driving the active pharmaceutical ingredient (API) market in India growth during the next few years. Also, increasing patent exercises and adoption of sustainable and environmentally friendly manufacturing practices will lead to sizable demand in the market.
The report on the active pharmaceutical ingredient (API) market in India covers the following areas:
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading active pharmaceutical ingredient (API) market in India vendors that include AbbVie Inc., Aurobindo Pharma Ltd., Cadila Pharmaceuticals Ltd., Cipla Inc., Divis Laboratories Ltd., DR Reddys Laboratories Ltd., Glenmark Pharmaceuticals Ltd., Granules India Ltd., Hetero Labs Ltd., Ind-Swift Laboratories Ltd., IOL Chemicals and Pharmaceuticals Ltd., Ipca Laboratories, J. B. Chemicals and Pharmaceuticals Ltd, Jubilant Pharmova Ltd., Laurus Labs Ltd., Lupin Ltd., Solara Active Pharma Sciences Ltd, Sun Pharmaceutical Industries Ltd., SUVEN PHARMACEUTICALS LTD., and Torrent Pharmaceuticals Ltd.. Also, the active pharmaceutical ingredient (API) market in India analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Exhibits: